OverviewSuggest Edit

QGel’s synthetic and tunable extracellular matrix (ECM) technology mimics the complex physiology of the human body, enabling the growth of any human or animal tissue in vitro. QGel enables drug development in a laboratory environment that accurately and reliably mimics the functioning of human organs, which means greater predictability of drug efficacy before the clinical phase. With an improved understanding of a drug’s potential, researchers spend more time and resources on the most promising therapies.
HQLausanne, CH

Latest Updates

Employees (est.) (Sept 2020)16
Cybersecurity ratingAMore

Key People/Management at QGel

Colin Sanctuary

Colin Sanctuary

Founder & CEO
Simone Rizzi

Simone Rizzi

Chief Scientific Officer
Show more

QGel Office Locations

QGel has an office in Lausanne
Lausanne, CH (HQ)
Route Cantonale
Show all (1)

QGel Financials and Metrics

Summary Metrics

Founding Date


QGel total Funding

$12 m

QGel latest funding size

$12 m

Time since last funding

4 years ago
QGel's latest funding round in December 2016 was reported to be $12 m. In total, QGel has raised $12 m
Show all financial metrics

QGel Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

QGel Online and Social Media Presence

Embed Graph

QGel Blogs

Organoids: bringing life to precision medicine

Swiss-based biotech QGel is hoping to offer a novel approach to precision medicine by solving several of the current challenges […]

QGel wins two separate global innovation awards from Fast Company and the Edison Awards

QGel has been awarded two prizes recognizing innovation and world changing ideas. On April 8, 2019, QGel was selected as […]

QGel awarded a High Commendation in the “Best Technological Innovation – Diagnostics” category at the 2018 Medtech Insight Awards

On September 23, 2018, QGel was awarded a High Commendation in the “Best Technological Innovation – Diagnostics” category at the […]

QGel, a tiny extracellular matrix gel with a big ambition: making cancer a manageable disease Innovation Forum

QGel is a Swiss start-up based at Lausanne’s Innovation Park, which develops synthetic extracellular matrices (ECM) for the growth of […]

Method of the Year 2017: Organoids

The ability to prod stem cells into three-dimensional tissue models makes for a powerful way to study human biology. But […]

Organoid Drug Screen for Breast Cancer: Personalized Medicine Breakthrough?

In a recent study, researchers developed a series of cell lines that may form the basis of a drug screen […]
Show more

QGel Frequently Asked Questions

  • When was QGel founded?

    QGel was founded in 2009.

  • Who are QGel key executives?

    QGel's key executives are Colin Sanctuary and Simone Rizzi.

  • How many employees does QGel have?

    QGel has 16 employees.

  • Who are QGel competitors?

    Competitors of QGel include Oasis Medical, PhaseBio Pharmaceuticals and TRB Chemedica.

  • Where is QGel headquarters?

    QGel headquarters is located at Route Cantonale, Lausanne.

  • Where are QGel offices?

    QGel has an office in Lausanne.

  • How many offices does QGel have?

    QGel has 1 office.